Suspected DRESS Syndrome
Rash + fever + systemic involvement 2-8 weeks after new drug
All Pathways
DermatologyEmergency
DRESS Syndrome Management
DRESS Syndrome Management: Suspected DRESS Syndrome → STOP Culprit Drug Immediately → Assess Clinical Features → Calculate RegiSCAR Score → RegiSCAR Int...
Pathway Overview
15 steps
Algorithm Steps
15 total
01Start 02Action STOP Culprit Drug Immediately
Identify and discontinue causative medication
- Top 5 culprits: Allopurinol, Vancomycin, Lamotrigine, Carbamazepine, TMP-SMX
- Other: Phenytoin, minocycline, dapsone, abacavir
- Onset typically 2-8 weeks after starting drug
- Can occur with drugs taken for years (rare)
03Action Assess Clinical Features
Key manifestations of DRESS
- Skin: Morbilliform eruption (90%), facial edema (50%)
- Fever: >38°C (90%)
- Lymphadenopathy: Present in 50-75%
- Hematologic: Eosinophilia >700/µL (90%), atypical lymphocytes
- Organ involvement: Liver (80%), kidney (40%), lung (30%), heart (rare but serious)
04Decision Calculate RegiSCAR Score
Validated diagnostic scoring system
- Fever ≥38.5°C: 0 (no/unknown), -1 (yes)
- Enlarged lymph nodes (≥2 sites, >1cm): 0 (no), 1 (yes)
- Eosinophilia: 0 (<700), 1 (700-1500), 2 (>1500 or if WBC<4000, eos>10%)
- Atypical lymphocytes: 0 (no), 1 (yes)
- Skin involvement: >50% BSA = 1
- Skin suggestive of DRESS (2/3: edema, infiltration, purpura, scaling): 1
- Biopsy suggesting DRESS: 0 (no), -1 (no/other diagnosis), 1 (yes)
- Organ involvement: 1 (one organ), 2 (≥2 organs)
- Resolution ≥15 days: -1 (no), 0 (yes)
- Evaluation for 3+ causes negative: 0 (no), 1 (yes)
05Action RegiSCAR Interpretation
Score determines likelihood of DRESS
- <2: No case (unlikely DRESS)
- 2-3: Possible case
- 4-5: Probable case
- ≥6: Definite case
- Note: More sensitive than Japanese SCAR criteria
06Action Initial Workup
Laboratory and imaging evaluation
- CBC with differential (eosinophils, atypical lymphocytes)
- LFTs (ALT/AST, bilirubin, ALP)
- Renal function (Cr, BUN)
- Cardiac: Troponin, BNP if symptoms, ECG
- Viral: HHV-6, HHV-7, EBV, CMV PCR/serology
- Consider: Chest X-ray, urinalysis, TSH
- Skin biopsy if diagnosis uncertain
07Action Mild DRESS
No significant organ dysfunction
- Skin-predominant symptoms
- Mild LFT elevation (<3x ULN)
- No cardiac, renal, or pulmonary involvement
- May manage outpatient with close follow-up
08Action Mild: Supportive Care
No systemic immunosuppression needed
- Topical high-potency corticosteroids
- Emollients for skin care
- Antihistamines for pruritus
- Monitor LFTs weekly initially
09Action Ongoing Monitoring
DRESS requires prolonged follow-up
- LFTs, renal function: Weekly during acute phase
- CBC with differential: Monitor eosinophils
- HHV-6 reactivation may cause symptom flare
- TSH at 2-3 months (autoimmune thyroiditis common)
- Monitor for autoimmune diseases (up to 3-5 years)
- Document culprit drug for future avoidance
10Outcome Resolution
Typical recovery 2-8 weeks after drug withdrawal
- Skin resolves first, organ dysfunction later
- Steroid taper slowly over 6-12 weeks
- Drug allergy documentation essential
- Cross-reactivity testing before related drugs
- Risk of late autoimmune sequelae
11Warning Complications / Death
Mortality ~10%, late sequelae common
- Hepatic failure, multi-organ failure
- Sepsis (especially during immunosuppression)
- Late autoimmune: Thyroiditis (most common), T1DM, lupus
- Recurrence with re-exposure to culprit/cross-reactive drugs
12Action Moderate DRESS
Single organ involvement
- Hepatitis (ALT >3x ULN)
- Renal impairment
- Significant eosinophilia (>5000/µL)
- Admit for monitoring
13Action Moderate: Systemic Corticosteroids
First-line immunomodulatory therapy
- Prednisone 0.5-1 mg/kg/day
- Or methylprednisolone IV if unable to take PO
- Continue until organ function normalizes
- Slow taper over 6-8 weeks minimum
- Rapid taper may cause flare
- Monitor for steroid side effects
- Path rejoins step 09Shared downstream outcome
14Warning Severe DRESS
Multi-organ or life-threatening
- Hepatic failure (ALT >10x ULN, jaundice)
- Renal failure
- Cardiac involvement (myocarditis)
- Pulmonary involvement
- Hemophagocytic lymphohistiocytosis (HLH)
- ICU admission often required
15Action Severe: Escalated Therapy
For steroid-resistant or multi-organ failure
- High-dose pulse steroids: Methylprednisolone 1g/day x 3 days
- Cyclosporine 3-5 mg/kg/day if steroid-refractory
- IVIG 2 g/kg over 2-5 days (controversial)
- Consider mycophenolate, rituximab for refractory cases
- Contraindicated during active sepsis: Rituximab
- Path rejoins step 09Shared downstream outcome
Guideline Source
Management of Adult Patients with DRESS: Delphi International Consensus
Clinical Safety Information
Clinical Decision Support — Not a Substitute for Clinical Judgment
Individual patient factors may require deviation from these recommendations.
Known Limitations
- Diagnosis can be challenging due to variable presentation
- Viral reactivation testing may not be available emergently
- Long-term monitoring required for autoimmune sequelae
- Steroid tapering requires individualization
- Cross-reactivity testing should guide future drug avoidance
Applicable Regions
USEU
Version 1Next review: 2027-01-11
Next steps
Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.
Related Resources
Frequently Asked Questions
What is the DRESS Syndrome Management?
The DRESS Syndrome Management is a emergency clinical algorithm for Dermatology. It provides a structured decision tree to guide clinical decision-making, based on Management of Adult Patients with DRESS: Delphi International Consensus.
What guideline is the DRESS Syndrome Management based on?
This algorithm is based on Management of Adult Patients with DRESS: Delphi International Consensus (DOI: 10.1001/jamadermatol.2023.4014).
What are the limitations of the DRESS Syndrome Management?
Known limitations include: Diagnosis can be challenging due to variable presentation; Viral reactivation testing may not be available emergently; Long-term monitoring required for autoimmune sequelae; Steroid tapering requires individualization; Cross-reactivity testing should guide future drug avoidance. Individual patient factors may require deviation from these recommendations.
Get AI-Powered Analysis Alongside This Algorithm
In AttendMe.ai, the DRESS Syndrome Management appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.
Try AttendMe Free